560 related articles for article (PubMed ID: 26861846)
1. Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia.
Montravers P; Harpan A; Guivarch E
Adv Ther; 2016 Feb; 33(2):151-66. PubMed ID: 26861846
[TBL] [Abstract][Full Text] [Related]
2. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
Werarak P; Kiratisin P; Thamlikitkul V
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
[TBL] [Abstract][Full Text] [Related]
3. A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study.
Quartin AA; Scerpella EG; Puttagunta S; Kett DH
BMC Infect Dis; 2013 Nov; 13():561. PubMed ID: 24279701
[TBL] [Abstract][Full Text] [Related]
4. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
Sandrock CE; Shorr AF
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
[TBL] [Abstract][Full Text] [Related]
5. Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.
Syed YY
Drugs; 2014 Sep; 74(13):1523-42. PubMed ID: 25117196
[TBL] [Abstract][Full Text] [Related]
6. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management.
Barbier F; Andremont A; Wolff M; Bouadma L
Curr Opin Pulm Med; 2013 May; 19(3):216-28. PubMed ID: 23524477
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA.
Horn KS; Danziger LH; Rodvold KA; Glowacki RC
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):463-472. PubMed ID: 28264613
[TBL] [Abstract][Full Text] [Related]
8. Ceftobiprole for the treatment of pneumonia: a European perspective.
Liapikou A; Cillóniz C; Torres A
Drug Des Devel Ther; 2015; 9():4565-72. PubMed ID: 26316697
[TBL] [Abstract][Full Text] [Related]
9. Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.
Drugs R D; 2006; 7(5):305-11. PubMed ID: 16922591
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia.
Chung DR; Song JH; Kim SH; Thamlikitkul V; Huang SG; Wang H; So TM; Yasin RM; Hsueh PR; Carlos CC; Hsu LY; Buntaran L; Lalitha MK; Kim MJ; Choi JY; Kim SI; Ko KS; Kang CI; Peck KR;
Am J Respir Crit Care Med; 2011 Dec; 184(12):1409-17. PubMed ID: 21920919
[TBL] [Abstract][Full Text] [Related]
11. Risk factor-based analysis of community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia: Microbiological distribution, antibiotic resistance, and clinical outcomes.
Hyun H; Song JY; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ
PLoS One; 2022; 17(6):e0270261. PubMed ID: 35767562
[TBL] [Abstract][Full Text] [Related]
12. Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia.
Scheeren TW
Future Microbiol; 2015; 10(12):1913-28. PubMed ID: 26573022
[TBL] [Abstract][Full Text] [Related]
13. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia.
Kaye KS; Udeani G; Cole P; Friedland HD
Hosp Pract (1995); 2015; 43(3):144-9. PubMed ID: 25956849
[TBL] [Abstract][Full Text] [Related]
14. Treatment options for nosocomial pneumonia due to MRSA.
Niederman MS
J Infect; 2009 Sep; 59 Suppl 1():S25-31. PubMed ID: 19766886
[TBL] [Abstract][Full Text] [Related]
15. Nosocomial pneumonia : rationalizing the approach to empirical therapy.
Andriesse GI; Verhoef J
Treat Respir Med; 2006; 5(1):11-30. PubMed ID: 16409013
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.
Torres A; Mouton JW; Pea F
Clin Pharmacokinet; 2016 Dec; 55(12):1507-1520. PubMed ID: 27272266
[TBL] [Abstract][Full Text] [Related]
17. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
Barriere SL
Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
[TBL] [Abstract][Full Text] [Related]
18. Emerging trends of nosocomial pneumonia in intensive care unit of a tertiary care public teaching hospital in Western India.
Bhadade R; Harde M; deSouza R; More A; Bharmal R
Ann Afr Med; 2017; 16(3):107-113. PubMed ID: 28671150
[TBL] [Abstract][Full Text] [Related]
19. [Adult hospital acquired pneumonia: a multicenter study on microbiology and clinical characteristics of patients from 9 Chinese cities].
Liu YN; Cao B; Wang H; Chen LA; She DY; Zhao TM; Liang ZX; Sun TY; Li YM; Tong ZH; Wang Z; He B; Yang W; Qu JM; Li XY; Chen RC; Ye F; Kang J; Li ER; Chen P; Zheng Y; Ma ZS; Ren J; Shi Y; Sun WK; Feng YL; Fan H; Jiang SJ; Zhang S; Xiong SD; Zuo P; Wang ZW
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Oct; 35(10):739-46. PubMed ID: 23289990
[TBL] [Abstract][Full Text] [Related]
20. Methicillin-resistant Staphylococcus aureus in community-acquired and health care-associated pneumonia: incidence, diagnosis, and treatment options.
Dean N
Hosp Pract (1995); 2010 Feb; 38(1):7-15. PubMed ID: 20469619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
